Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage European companies.

Our current portfolio comprises biotech, medtech and diagnostics companies, all working to develop truly disruptive solutions for high unmet medical needs.

Dezima and Acerta, multi-billion Euro success stories

BioGeneration was co-founder and investor in two of the most successful biotech startups in Europe: Acerta Pharma and Dezima Pharma. Acerta Pharma develops a new drug for the treatment of hematologic malignancies (leukemia) and was sold to AstraZeneca for up to US$ 7 billion. Dezima Pharma is developing a treatment for of a cardiovascular disorder (dyslipidemia) and was sold to Amgen for a deal amount of up to US$ 1.5 billion.

Shaping new life-science ventures

Our varied and complementary experience has been gained from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

Confo Therapeutics reports grant of two key patents for ConfoBodies

Dec 2, 2019

Ghent, Belgium, 2 December 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been granted two key ConfoBodyTM patents derived from the patent estate known as the “Steyaert patents”. The Steyaert patents – named after Prof. Jan...

NST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)

Sep 25, 2019

NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, today announces dosing of the first patient with...

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

Sep 23, 2019

Ghent, Belgium, 23 September 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology...

NorthSea Therapeutics strengthens its management team with the appointment of Mats Blom as CFO

Sep 4, 2019

Naarden, The Netherlands, 4 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, today announces the appointment of...

News overview

Next events

JP Morgan 38th Annual Healthcare Conference San Fransisco – January 13 / 16

Nov 18, 2019

Edward, Oskar and Daniela will attend JP Morgan 2020 https://digitalhealthtoday.com/events/jp-morgan-global-healthcare-conference/

Innovation for Health Rotterdam – February 13

Jul 4, 2019

Max will attend the Innovation for Health conference in Rotterdam. https://www.innovationforhealth.nl/

Event overview

Latest investments

Portfolio